drugset / Trial / NCT05091541
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-armed, open-label,multicenter Phase 1/2 study to evaluate the safety and efficacy of CT120 in subjects with relapsed/refractory B-cell non-Hodgkin's lymphoma.
Timeline
- Start
- 2021-10-20
- Primary completion
- 2024-10-20
- Completion
- 2039-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT120 | Cell therapy | 1e+06 cells/kg | — |
| Subject | CT120 | Cell therapy | 3e+06 cells/kg | — |
| Subject | CT120 | Cell therapy | 6e+06 cells/kg | — |